Comparison of intestinal permeability of nebivolol hydrochloride loaded solid lipid nanoparticles with commercial nebivolol tablet

dc.authorid0000-0002-3210-3747
dc.contributor.authorGökçe, Evren Homan
dc.contributor.authorKaynak, Mustafa Sinan
dc.contributor.authorYurdasiper, Aysu
dc.contributor.authorÜstündağ Okur, Neslihan
dc.contributor.authorŞahin, Selma
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T20:01:30Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T20:01:30Z
dc.date.issued2018
dc.departmentİstanbul Medipol Üniversitesi, Eczacılık Fakültesi, Eczacılık Teknolojisi Bölümü, Farmasötik Teknoloji Ana Bilim Dalı
dc.descriptionWOS: 000458080300013
dc.description.abstractThe oral application of drugs is the most popular route for achieving systemic effects, nevertheless, it is limited by difficulties related to physicochemical properties of the drug. Solid lipid nanoparticles (SLNs) are appealing extensive notice because of showing increased solubility and improved oral bioavailability via different mechanisms. The aim of the study is to compare and peruse the in-situ permeation of nebivolol (NBV) loaded SLN and its commercial tablet formulation used for the treatment of hypertension. For this aim Single-Pass Intestinal Perfusion (SPIP) method was used for in-situ permeation studies. NBV loaded SLNs were prepared and modified with polyethylene glycol (PEG). In order to prepare SLNs by homogenization technique, compritol, lecithin and poloxamer were chosen. Particle sizes of blank and loaded SLN were 213.4 +/- 17.5 and 264.1 +/- 18.8 nm, respectively with polydispersity index values of approximately 0.3 for each. NBV loading resulted in positive electrical charge on SLNs. The encapsulation efficiency was 98.04 +/- 0.2 %. Permeability coefficient values were tripled when NBV was incorporated in SLNs and doubled when pure NBV was given separately with a blank SLN. PEG modified SLN can be used to enhance oral absorption of NBV, and SLNs alone can be used as permeation enhancer in oral drug delivery..
dc.description.sponsorshipTUBITAK [112S292]en_US
dc.description.sponsorshipThis study was supported by TUBITAK Project No: 112S292. The authors would like to thank Novartis (Novartis Drug Co., Turkey) for providing metoprolol tartrate. The authors would also like to thank to Ege University, Faculty of Pharmacy, Pharmaceutical Sciences Research Center (FABAL) for high pressure homogenization facilities.en_US
dc.identifier.citationGökçe, E. H., Kaynak, M. S., Yurdasiper, A., Üstündağ-Okur, N. ve Şahin, S. (2018). Comparison of intestinal permeability of nebivolol hydrochloride loaded solid lipid nanoparticles with commercial nebivolol tablet. Marmara Pharmaceutical Journal, 22(4), 578-586. https://dx.doi.org/10.12991/jrp.2018.100
dc.identifier.doi10.12991/jrp.2018.100
dc.identifier.endpage586
dc.identifier.issn2630-6344
dc.identifier.issue4
dc.identifier.scopusqualityQ3
dc.identifier.startpage578
dc.identifier.urihttps://dx.doi.org/10.12991/jrp.2018.100
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3307
dc.identifier.volume22
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherMarmara University
dc.relation.ecinfo:eu-repo/grantAgreement/TUBITAK/SOBAG/112S292
dc.relation.ispartofMarmara Pharmaceutical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectSolid Lipid Nanoparticle
dc.subjectNebivolol
dc.subjectSegmental Permeability
dc.subjectIntestinal Absorption
dc.titleComparison of intestinal permeability of nebivolol hydrochloride loaded solid lipid nanoparticles with commercial nebivolol tablet
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Ustundağ Okur, Neslihan.pdf
Boyut:
1.26 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text